Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Raises $15.4 Million in Private Stock Offering

NEW YORK (GenomeWeb) – MdxHealth announced today that it has raised €12.3 milllion ($15.4 million) in a private placement. The firm sold 3.4 million shares at €3.60 per share to a group of institutional, qualified and professional investors.

"In combination with our existing cash position, these funds allow us to support and scale up MDxHealth's US-based managed care and related healthcare reimbursement efforts," Jan Groen, CEO of MDxHealth, said in a statement. "In addition, it will allow us to accelerate product development and finance general corporate purposes."

Petercam was the sole lead manager and book runner in the placement.

The announcement comes a day after MDxHealth reported Q3 revenues were up 78 percent year over year, driven by growth in its prostate cancer molecular diagnostic test, ConfirmMDx. It also announced the private placement on Tuesday.

MDxHealth is a molecular diagnostics company with offices in Herstal, Belgium and Irvine, Calif., and develops epigenetic tests for cancer assessment.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.